Valeant Pharmaceuticals International Inc , Canada's largest listed drugmaker, on Tuesday forecast 2014 adjusted earnings of $8.25 to $8.75 per share and revenue of $8.2 billion to $8.6 billion, both up about 40 percent from the previous year. Analysts on average were expecting 2014 adjusted earnings per share of $8.71 and revenue of $8.279 billion, according to Thomson Reuters I/B/E/S.
Thomson Reuters Corporation (Thomson Reuters) is a provider of information for the world?s businesses and professionals. Shares of TRI fell by 0.19% or $-0.07/share to $37.57. In the past year, the shares have traded as low as $29.10 and as high as $38.73. On average, 779251 shares of TRI exchange hands on a given day and today's volume is recorded at 686275.
Thomson Reuters Corporation (Thomson Reuters) is a provider of information for the world?s businesses and professionals. Shares of TRI traded higher by 0.1% or $0.04/share to $40.05. In the past year, the shares have traded as low as $28.75 and as high as $40.70. On average, 926387 shares of TRI.TO exchange hands on a given day and today's volume is recorded at 586454.
Valeant Pharmaceuticals International, Inc., formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. Shares of VRX fell by 3.88% or $-4.54/share to $112.62. In the past year, the shares have traded as low as $61.10 and as high as $118.25. On average, 1082480 shares of VRX exchange hands on a given day and today's volume is recorded at 2403894.
Valeant Pharmaceuticals International, Inc., formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. Shares of VRX fell by 3.72% or $-4.63/share to $119.99. In the past year, the shares have traded as low as $60.29 and as high as $125.71. On average, 358895 shares of VRX.TO exchange hands on a given day and today's volume is recorded at 462255.
Source
